Merck & Co., Inc. (FRA:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 172.86B |
| Revenue (ttm) | 59.14B |
| Net Income (ttm) | 16.13B |
| Shares Out | n/a |
| EPS (ttm) | 6.36 |
| PE Ratio | 10.72 |
| Forward PE | 8.98 |
| Dividend | 2.91 (4.28%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 2,483 |
| Average Volume | 3,305 |
| Open | 68.20 |
| Previous Close | 68.70 |
| Day's Range | 67.40 - 68.50 |
| 52-Week Range | 65.50 - 125.20 |
| Beta | n/a |
| RSI | 40.31 |
| Earnings Date | Jul 29, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
US stocks threatens to close at record levels but closes just off record levels
The broader stock indices threatened to close at record levels with the S&P index getting within one point of a record high level. The comes in at 6147.43. The high price today reached 6146.52. The NA...
Merck's RSV shot for infants gets key approval despite RFK Jr.'s panel shakeup
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has previously made statements skeptical of vaccines, is now recommending the respiratory syncytial virus (RSV) vaccine for infants...
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated (NYSE: ELAN) appears to be turning a corner . What Happened : Investor meetings hosted by Wi...
ACIP Recommends Use of Merck’s ENFLONSIA (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) v...
ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.
New vaccine panel meeting underway
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.
RFK Jr’s vaccine panel recommends new RSV treatment for infants
Move comes after health secretary replaced advisory board with ideological allies and several vaccine skeptics Health secretary Robert F Kennedy Jr ’s reconstituted vaccine advisory panel recommended ...
RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants
The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.
ACIP recommends Merck's RSV shot for infants under 8 months old
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news from the CDC.
Merck wins CDC AdCom backing for RSV shot
ACIP recommends Merck's RSV shot for infants under 8 months old
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news from the CDC.
US CDC panel votes in favor of Merck's RSV antibody drug
An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, who...
4 stocks to watch on Wednesday: MRK, BMBL, GIS, MU
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effect...
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview...
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention.
Merck succeeds in late-stage study of PAH treatment
Merck Announces Phase 3 HYPERION Study of WINREVAIR (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo...
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (...
Major US stocks close mixed. Dow is lower. S&P near unchanged. NASDAQ marginally higher
The major US stock indices closed the day with mixed results following the FOMC decision to keep rates unchanged, as widely expected. The Dow Jones Industrial Average slipped modestly, while the S&P 5...
Merck viewed favorably as CDC excludes HPV vaccines in ACIP agenda
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, c...
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used...
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
CEL-SCI Corporation (NYSE American: CVM) today applauded the U.S. Food and Drug Administration’s (FDA) approval of Merck’s KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, for the treatment of adult pa...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...